FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
KYMR Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-194.5M
-102.83M
-153.09M
-128.95M
Net Income
-223.86M
-146.96M
-154.81M
-100.22M
Depreciation & Amortization
7.37M
3.56M
2.98M
2.4M
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
55.01M
43.12M
35.48M
24.97M
Change in Working Capital
-23.97M
2.68M
-37.62M
-61.92M
Accounts Receivable
15M
-15M
-2.4M
577k
Inventory
0
23.37M
2.4M
8.71M
Accounts Payable
-307k
2.04M
253k
54k
Other Working Capital
-38.66M
-7.73M
-37.88M
-71.26M
Other Non-Cash Items
-9.06M
-5.23M
889k
5.83M
CF from Investing Activities
-404.08M
139.89M
20.52M
-99.83M
Investments in Property, Plant & Equipment
-12.84M
-34.48M
-2.84M
-1.6M
Net Acquisitions
0
0
-20.52M
5.81M
Investment Purchases
-901.23M
-189.15M
-445.97M
-456.4M
Sales/Maturities of Investments
496M
363.52M
469.33M
358.17M
Other Investing Activites
13.98M
0
20.52M
-5.81M
CF from Financing Activities
608.85M
4.19M
153M
250.28M
Debt Repayment
-1.58M
-76k
-1.13M
-849k
Common Stock Issued
596.62M
4.27M
149.82M
243.11M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
13.81M
4.27M
4.3M
8.02M
Free Cash Flow
-207.34M
-137.31M
-155.92M
-130.54M
Operating Cash Flow
-194.5M
-102.83M
-153.09M
-128.95M
Capital Expenditures
-12.84M
-34.48M
-2.84M
-1.6M
Cash at Beginning of Period
115.78M
74.53M
54.09M
32.59M
Cash at End of Period
126.05M
115.78M
74.53M
54.09M
Net Change In Cash
10.27M
41.25M
20.43M
21.5M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-530.75M
-383.79M
-228.98M
-128.76M
Net Income
-223.86M
-146.96M
-151.83M
-98M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-754.61M
-530.75M
-383.79M
-228.98M
Other Distributions
-223.86M
-146.96M
-154.81M
-100.22M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
97.86M
101.08M
13.33M
11.88M
Annual Depreciation
7.37M
3.56M
2.98M
2.4M
Capital Expenditure
-12.84M
-34.48M
-2.84M
-1.6M
Net PPE
103.33M
131.99M
13.19M
11.08M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
